Page 11 - Delaware Medical Journal - November 2017
P. 11
CANCER CLINICAL TRIAL
ECOG E1A11:
PROTOCOL OF THE MONTH
Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone
To compare the overall survival between two strategies of lenalidomide maintenance following induction with a proteasome inhibitor–IMiD
To compare the progression-free survival between two strategies of lenalidomide maintenance following induction with a
Treatment:
ARM A:
Repeat cycles every 3 weeks for a total of 12 cycles
ARM B:
Repeat cycles every 4 weeks for a total of 9 cycles
ARM C:
Repeat cycles every 4 weeks for 24 Cycles
ARM D:
The Delaware Cancer Treatment Program (DCTP) provides medical insurance coverage to uninsured Delawareans for
For information regarding clinical trials
or if you would like to have the list of open protocols e-mailed to you, akee@christianacare.org.
Del Med J | November 2017 | Vol. 89 | No. 11 331
